Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record.

MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN

Open access
Xue, Xinying, Liu, Yuxia, Wang, Yong, Meng, Mingming, Wang, Kaifei, Zang, Xuefeng, Zhao, Sheng, Sun, Xiaohua, Cui, Lei, Pan, Lei, Liu, Sanhong · 2016 · Oncotarget

Abstract

// Xinying Xue 1, 2 , Yuxia Liu 3 , Yong Wang 1 , Mingming Meng 4 , Kaifei Wang 2 , Xuefeng Zang 5 , Sheng Zhao 6 , Xiaohua Sun 7 , Lei Cui 8 , Lei Pan 1 , Sanhong Liu 9 1 Department of Special Medical Treatment-Respiratory Disease, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 2 Department of Respiratory Diseases of Chinese PLA General Hospital, Beijing, China 3 Department of Research, Peking Union Medical Collage Hospital, Beijing, China 4 Department of Gastroenterology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 5 Department of Intensive Care Unit, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 6 Department of Cardiology, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Beijing, China 7 Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai, China 8 Department of Central Laboratory, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 9 Shanghai Institute of Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China Correspondence to: Lei Pan, email: leipan2010@163.com Sanhong Liu, email: liush@shanghaitech.edu.cn Lei Cui, email: cuileite@aliyun.com Keywords: non-small cell lung carcinoma, miR-21, miR-155, SOCS1, SOCS6 Received: July 11, 2016 Accepted: October 25, 2016 Published: November 02, 2016 ABSTRACT Lung cancer remains the leading cause of cancer-associated death worldwide. MiR-21 and miR-155 are the most amplified miRNAs in non-small cell lung carcinoma (NSCLC), and are critical promoters of NSCLC progression. However, it remains unclear how miR-21 and miR-155 induce cancer progression, and whether these miRNAs share common targets, such as tumor suppressor genes required to prevent NSCLC. Here we report that miR-21 and miR-155 levels are elevated in NSCLC and are proportional to the progression of the disease. In addition, miR-21 and miR-155 share nearly 30% of their predicted target genes, including SOCS1 , SOCS6 , and PTEN , three tumor suppressor genes often silenced in NSCLC. Consequently, antagonizing miR-21, miR-155 or both potently inhibited tumor progression in xenografted animal models of NSCLC. Treatment with miR-21 and miR-155 inhibitors in combination was always more effective against NSCLC than treatment with a single inhibitor. Furthermore, levels of miR-21 and miR-155 expression correlated inversely with overall and disease-free survival of NSCLC patients. Our findings reveal that miR-21 and miR-155 promote the development of NSCLC, in part by downregulating SOCS1 , SOCS6 , and PTEN . Combined inhibition of miR-21 and miR-155 could improve the treatment of NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.13022

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Xue, X., Liu, Y., Wang, Y., Meng, M., Wang, K., Zang, X., Zhao, S., Sun, X., Cui, L., Pan, L., & Liu, S.
Venue
Oncotarget
Published
2016-11-02
Volume
7
Issue
51
Pages
84508-84519
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2548791365
Cited by
186
References
0
FWCI
7.04
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.